MCID: NNT008
MIFTS: 41

Neonatal Abstinence Syndrome

Categories: Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

MalaCards integrated aliases for Neonatal Abstinence Syndrome:

Name: Neonatal Abstinence Syndrome 12 43 15 17 71
Drug Withdrawal Syndrome in Newborn 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9828
ICD9CM 34 779.5
MeSH 43 D009357
SNOMED-CT 67 414819007
ICD10 32 P96.1
UMLS 71 C0027609 C1332133

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to opiate dependence and withdrawal disorder. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Drug metabolism - cytochrome P450. The drugs Phenobarbital and Opium have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and liver.

Related Diseases for Neonatal Abstinence Syndrome

Diseases related to Neonatal Abstinence Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 30.1 PDYN OPRM1 OPRL1 OPRK1 OPRD1
2 withdrawal disorder 30.0 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
3 opioid addiction 29.9 PNOC OPRM1 OPRK1 OPRD1 CYP2B6 COMT
4 disease of mental health 29.4 PDYN OPRM1 OPRL1 OPRK1 OPRD1 COMT
5 drug dependence 28.9 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
6 substance abuse 28.8 PDYN OPRM1 OPRL1 OPRK1 OPRD1 CYP2D6
7 opioid abuse 28.8 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
8 diarrhea 28.7 OPRM1 OPRK1 OPRD1 CYP3A4 CYP2D6 CYP2B6
9 pain agnosia 27.9 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
10 migraine with or without aura 1 27.4 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
11 tremor 10.5
12 barbiturate abuse 10.2 OPRM1 CLMP
13 cannabis abuse 10.2 OPRM1 COMT
14 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
15 sickle cell disease 10.1
16 ichthyosis, congenital, autosomal recessive 9 10.1 HECTD4 COMT
17 tardive dyskinesia 10.1 CYP2D6 COMT
18 impulse control disorder 10.1 OPRM1 COMT
19 schaaf-yang syndrome 10.1 OPRM1 OPRL1 OPRD1
20 torticollis 10.1
21 syphilis 10.1
22 hypoglycemia 10.1
23 chronic pain 10.1
24 pik3ca-related overgrowth syndrome 10.1
25 mixed epithelial stromal tumour 10.1 CYP3A4 COMT
26 paralytic ileus 10.0 OPRM1 CYP3A4
27 trigeminal nerve disease 9.9 OPRM1 OPRL1 OPRK1 OPRD1
28 trigeminal neuralgia 9.9 OPRM1 OPRL1 OPRK1 OPRD1
29 cleft palate, isolated 9.9
30 strabismus 9.9
31 enterocolitis 9.9
32 sudden infant death syndrome 9.9
33 major affective disorder 8 9.9
34 major affective disorder 9 9.9
35 fetal alcohol syndrome 9.9
36 alcohol-related birth defect 9.9
37 zika fever 9.9
38 microcephaly 9.9
39 visual epilepsy 9.9
40 oligohydramnios 9.9
41 hepatitis c 9.9
42 post-traumatic stress disorder 9.9
43 hemoglobinopathy 9.9
44 bipolar disorder 9.9
45 mood disorder 9.9
46 adjustment disorder 9.9
47 acute stress disorder 9.9
48 myocarditis 9.9
49 polycythemia 9.9
50 perinatal necrotizing enterocolitis 9.9

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
2
Opium Approved, Illicit Phase 4 8008-60-4
3
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Clonidine Approved Phase 4 4205-90-7 2803
6 Opium Poppy Phase 4
7 Neurotransmitter Agents Phase 4
8 Adrenergic alpha-Agonists Phase 4
9 Antihypertensive Agents Phase 4
10 Adrenergic Agents Phase 4
11 Sympatholytics Phase 4
12 Adrenergic Agonists Phase 4
13 Pharmaceutical Solutions Phase 4
14
tannic acid Approved Phase 3 1401-55-4
15
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
16
Chamomile Approved, Experimental, Investigational Phase 3
17
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
18
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
19
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 446220 5760
20
Chloroprocaine Approved Phase 3 133-16-4 8612
21 Excitatory Amino Acid Antagonists Phase 3
22 Hypnotics and Sedatives Phase 3
23 GABA Modulators Phase 3
24 Anticonvulsants Phase 3
25 Opiate Alkaloids Phase 3
26 English Lavender Phase 3
27 Antiemetics Phase 3
28 Psychotropic Drugs Phase 3
29 Gastrointestinal Agents Phase 3
30 Antipsychotic Agents Phase 3
31 Dopamine Agents Phase 3
32 Dopamine Antagonists Phase 3
33 Anesthetics Phase 3
34 Anesthetics, Local Phase 3
35
Ondansetron Approved Phase 2 99614-02-5 4595
36 Anti-Anxiety Agents Phase 2
37 Dermatologic Agents Phase 2
38
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
39
Methadone Approved 76-99-3 4095
40
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
41
Ethanol Approved 64-17-5 702
42
Hydrocortisone Approved, Vet_approved 50-23-7 5754
43
Hydrocortisone acetate Approved, Vet_approved 50-03-3
44
Naltrexone Approved, Investigational, Vet_approved 16590-41-3 5360515
45 Analgesics, Non-Narcotic
46 Respiratory System Agents
47 Antitussive Agents
48 Chlorpheniramine, phenylpropanolamine drug combination
49 Liver Extracts
50 Hydrocortisone 17-butyrate 21-propionate

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Unknown status NCT02851303 Phase 4 Morphine;Methadone
2 Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
4 Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS). Completed NCT01804075 Phase 4 Methadone;Morphine
5 Long Acting Subcutaneous Compared to Short Acting Sublingual Buprenorphine Administration in Pregnant and Lactating Women Recruiting NCT04212065 Phase 4 buprenorphine
6 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
7 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Not yet recruiting NCT04298853 Phase 4 Morphine PRN;Morphine scheduled
8 Clonidine as Adjunct to Morphine in the Management of Term and Near Term Infants With Neonatal Abstinence Syndrome Suspended NCT03762317 Phase 4 Clonidine;Placebo
9 Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology Withdrawn NCT03740243 Phase 4 Buprenorphine/naloxone;Buprenorphine
10 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
11 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Completed NCT03097484 Phase 3 lavender and chamomile essential oils
12 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
13 A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
14 Pharmacological Treatment of Narcotic Neonatal Withdrawal Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
15 Can Maternal Acupuncture for Chemically Dependent Pregnant Women Reduce the Severity of Neonatal Abstinence Syndrome? - A Randomized Controlled Trial Completed NCT00225316 Phase 3
16 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
17 Improving Outcomes in Neonatal Abstinence Syndrome Completed NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
18 Maternal Opioid Treatment: Human Experimental Research Completed NCT00271219 Phase 3 Methadone;Buprenorphine
19 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
20 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
21 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations Not yet recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
22 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study Not yet recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
23 An Evaluation of Intraabdominal Chloroprocaine During Cesarean Delivery and Its Effect on Postoperative Pain and Nausea; a Randomized Controlled Trial & Pharmacokinetic-pharmacodynamics (PKPD) Analysis. Not yet recruiting NCT03260972 Phase 3 Chloroprocaine Hcl 2% Inj;Normal saline
24 Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants: Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
25 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
26 Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial Completed NCT00510016 Phase 2 Clonidine HCL
27 A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS) Completed NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
28 Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
29 Modeled Dose Exposure of Sublingual Buprenorphine in the Neonatal Opioid Abstinence Syndrome Completed NCT03608696 Phase 1, Phase 2 Buprenorphine
30 Prevention of Neonatal Abstinence Syndrome Completed NCT01801475 Phase 1, Phase 2 Ondansetron
31 Maternal Buprenorphine-naloxone Treatment During the Perinatal Period: Fetal and Infant Effects Recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
32 AIM 2- Prevention of Neonatal Abstinence Syndrome Recruiting NCT01965704 Phase 2 Ondansetron;Placebo
33 Pharmacologically-based Strategies for Buprenorphine Treatment During Pregnancy Recruiting NCT03831113 Phase 2 Buprenorphine: Magnitude Group;Buprenorphine: Frequency Group;Buprenorphine: Dosing Group
34 Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Suspended NCT03670160 Phase 2 Phenobarbital;Clonidine
35 Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome Terminated NCT03134703 Phase 2 Methadone;Morphine
36 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
37 A Randomized, Open Label Clinical Trial of Buprenorphine in the Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
38 Interest of Concentrations in Meconium of Drugs Used for Treatment of Pregnant Opioid-dependent Woman as a Prognostic Factor of Time, Severity and Duration of Neonatal Abstinence Syndrome Completed NCT03334981
39 The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates Completed NCT01754324 Methadone
40 Methadone, Buprenorphine and Fetal Neurobehavior Completed NCT00653692
41 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
42 Feasibility of Auricular Acupressure as an Adjunct Treatment for Neonatal Abstinence Syndrome (NAS) Completed NCT03973801
43 Retrospective Analysis of the Utility Formal Psychosocial Support in Enhancing the Outcome of Pregnancies in Opiate-addicted Pregnant Women in Agonist Maintenance Programs Completed NCT01889121
44 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome: A Randomized Controlled Trial Completed NCT02872077
45 Acupuncture Use in Infants Treated for Neonatal Abstinence Syndrome: a Pilot Study Completed NCT02062151
46 Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior Completed NCT00218621
47 The Use of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome (NAS) Completed NCT03113656
48 Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome Completed NCT03549936
49 Mother vs. Child? Healthcare Worker Perceptions of Conflict Between Maternal Autonomy and Child Health When Providing Care for Pregnant Women Engaging in Problematic Substance Use Completed NCT02797990
50 Donor Human Milk for Infants With Neonatal Abstinence Syndrome Completed NCT02182973

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

40
Brain, Skin, Liver, Breast, Placenta, Testes, Fetal Brain

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 918)
# Title Authors PMID Year
1
Integrative Review of Gut Microbiota and Expression of Symptoms Associated with Neonatal Abstinence Syndrome. 61
32555010 2020
2
Developmental Outcomes of Children Born with Neonatal Abstinence Syndrome (NAS): A Scoping Review. 61
32495712 2020
3
Long-term Healthcare Utilization by Medicaid Enrolled Children with Neonatal Abstinence Syndrome. 61
32446493 2020
4
Knowledge of and Perceived Competence in Trauma-Informed Care and Attitudes of NICU Nurses Toward Mothers of Newborns With Neonatal Abstinence Syndrome. 61
32553592 2020
5
Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study. 61
31567599 2020
6
Intrauterine Substance Exposure and the Risk for Subsequent Physical Abuse Hospitalizations. 61
32081768 2020
7
Salivary cortisol levels as a biomarker for severity of withdrawal in opioid-exposed newborns. 61
31578040 2020
8
Expanding Contraception Access for Women With Opioid-Use Disorder: A Qualitative Study of Opportunities and Challenges. 61
32468826 2020
9
Clinical and basic research investigations into the long-term effects of prenatal opioid exposure on brain development. 61
32459039 2020
10
Perceived Barriers to Contraceptive Access and Acceptance among Reproductive-Age Women Receiving Opioid Agonist Therapy in Northeast Tennessee. 61
32358615 2020
11
Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization. 61
32423682 2020
12
Evaluation and analysis of the Modified Finnegan Scoring System for assessment of neonatal abstinence syndrome. 61
32421839 2020
13
Neonatal Abstinence Syndrome In The United States, 2004-16. 61
32364857 2020
14
Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. 61
32424335 2020
15
Behavioral development in children with prenatal substance exposure and neonatal abstinence syndrome: Associated factors and implications. 61
32275115 2020
16
State Policies That Treat Prenatal Substance Use As Child Abuse Or Neglect Fail To Achieve Their Intended Goals. 61
32364867 2020
17
Monitoring Prenatal Exposure to Buprenorphine and Methadone. 61
31425444 2020
18
Infant and Maternal Outcomes for Women Who Experience Imprisonment in Ontario, Canada: A Retrospective Cohort Study. 61
31948864 2020
19
Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. 61
31820437 2020
20
Association of a Simplified Finnegan Neonatal Abstinence Scoring Tool With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome. 61
32267513 2020
21
Developmental and behavioral outcomes of children with neonatal abstinence syndrome. 61
32204794 2020
22
Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. 61
31987653 2020
23
Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. 61
31809406 2020
24
Implementing a Learning Collaborative Framework for States Working to Improve Outcomes for Vulnerable Populations: The Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community. 61
32176568 2020
25
Safety, Feasibility, and Effectiveness of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome: A Crossover Randomized Controlled Trial. 61
32243324 2020
26
On "'Choose Physical Therapy' for Neonatal Abstinence Syndrome: Clinical Management for Infants Affected by the Opioid Crisis." McCarty DB, Peat JR, O'Donnell S, Graham E, Malcolm, WF. Phys Ther. 2019; 99;771-785. 61
32163160 2020
27
The Association of Concomitant Maternal Marijuana Use on Health Outcomes for Opioid Exposed Newborns in Massachusetts, 2003-2009. 61
31843217 2020
28
Screening for Opioid and Stimulant Exposure in utero via Targeted and Untargeted Metabolomics Analysis of Umbilical Cords. 61
32142018 2020
29
Inclusion of Positive Self-reporting by Mothers of Substance Exposed Neonates Increases the Predictability of NAS Severity Over Toxicology Alone. 61
31916143 2020
30
Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Practical Applications and Clinical Impact. 61
32232496 2020
31
High Prevalence of Buprenorphine in Prenatal Drug Screens in an Appalachian City. 61
32123924 2020
32
Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review. 61
32164782 2020
33
Neonatal Abstinence Syndrome: Leveraging Health Information Technology to Develop a Data-Driven National Policy Approach. 61
32027558 2020
34
The Effects of Neonatal Abstinence Syndrome on Language Delay from Birth to 10 Years. 61
31923742 2020
35
Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey. 61
31911649 2020
36
Emerging therapies for the treatment of neonatal abstinence syndrome. 61
32146833 2020
37
OB/GYN perceptions of Prescription Drug Monitoring Programs as a primary prevention tool for neonatal abstinence syndrome. 61
32265114 2020
38
Development and application of a primer and reference assessment tool for neonatal abstinence syndrome: A phase I pilot study. 61
31867467 2020
39
Using Simulation in Training Pediatric Residents on Neonatal Abstinence Syndrome Scoring: An Experimental Study. 61
32243322 2020
40
Aromatherapy as an adjunctive therapy for neonatal abstinence syndrome: A pilot study. 61
32329887 2020
41
One-Year Postpartum Mental Health Outcomes of Mothers of Infants with Neonatal Abstinence Syndrome. 61
31925632 2020
42
Neonatal Abstinence Syndrome and Childhood Mental Health Conditions, 2009-2015: Commercial Versus Medicaid Populations. 61
31615364 2020
43
2019 Update on Pediatric Medical Overuse: A Systematic Review. 61
32011675 2020
44
Neonatal intensive care unit admissions before and after the adoption of the baby friendly hospital initiative. 61
32089022 2020
45
Neonatal Abstinence Syndrome among Infants Born to Mothers with Sickle Cell Hemoglobinopathies. 61
31756755 2020
46
An Update on the Burden of Neonatal Abstinence Syndrome in the United States. 61
31932280 2020
47
The Parental Experience of Newborns With Neonatal Abstinence Syndrome Across Inpatient Care Settings: A Qualitative Study. 61
32039935 2020
48
A New Scoring System for the Assessment of Neonatal Abstinence Syndrome. 61
31777045 2020
49
Evaluating the effect of hospital setting on outcomes for neonatal abstinence syndrome. 61
32086436 2020
50
Development of an abbreviated symptom score for the neonatal abstinence syndrome. 61
32076111 2020

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

Pathways related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
2
Show member pathways
12.62 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3
Show member pathways
11.76 UGT2B7 CYP3A4 CYP2D6 CYP2B6
4
Show member pathways
11.68 CYP3A4 CYP2D6 CYP2B6 COMT
5
Show member pathways
11.6 CYP3A4 CYP2D6 CYP2B6
6
Show member pathways
11.5 UGT2B7 CYP3A4 CYP2D6 CYP2B6
7
Show member pathways
11.39 CYP3A7 CYP3A4 COMT
8
Show member pathways
11.28 UGT2B7 CYP3A7 CYP3A4 COMT
9
Show member pathways
11.18 UGT2B7 CYP3A4 CYP2D6
10 11.14 CYP3A4 CYP2B6
11
Show member pathways
11.14 UGT2B7 CYP3A4 COMT
12
Show member pathways
11.12 CYP3A4 CYP2D6
13 11.08 CYP3A4 CYP2B6
14
Show member pathways
10.91 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
15 10.87 UGT2B7 CYP3A4
16
Show member pathways
10.85 UGT2B7 CYP3A4 CYP2D6 CYP2B6
17
Show member pathways
10.76 CYP3A4 CYP2D6
18 10.72 UGT2B7 CYP2D6
19 10.58 UGT2B7 CYP2D6 CYP2B6
20 10.49 UGT2B7 CYP2D6

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.14 UGT2B7 OPRM1 OPRL1 OPRK1 OPRD1 HECTD4
2 endoplasmic reticulum GO:0005783 9.93 UGT2B7 OPRM1 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3 endoplasmic reticulum membrane GO:0005789 9.91 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4 intracellular membrane-bounded organelle GO:0043231 9.85 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
5 neuron projection GO:0043005 9.73 OPRM1 OPRL1 OPRK1 OPRD1
6 dendrite GO:0030425 9.65 PNOC PDYN OPRM1 OPRK1 COMT
7 integral component of presynaptic membrane GO:0099056 9.5 OPRM1 OPRK1 OPRD1
8 integral component of synaptic vesicle membrane GO:0030285 9.49 OPRK1 OPRD1
9 dendrite membrane GO:0032590 9.48 OPRM1 OPRD1
10 axon terminus GO:0043679 9.26 PNOC PDYN OPRK1 OPRD1
11 spine apparatus GO:0097444 9.16 OPRM1 OPRD1
12 organelle membrane GO:0031090 9.02 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.1 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
2 xenobiotic metabolic process GO:0006805 9.8 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3 steroid metabolic process GO:0008202 9.8 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.78 OPRM1 OPRK1 OPRD1
5 sensory perception of pain GO:0019233 9.75 OPRM1 OPRL1 OPRK1
6 retinol metabolic process GO:0042572 9.74 CYP3A7 CYP3A4 CYP2D6
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.73 OPRM1 OPRL1 OPRK1 OPRD1
8 exogenous drug catabolic process GO:0042738 9.7 CYP3A4 CYP2D6 CYP2B6
9 drug metabolic process GO:0017144 9.69 CYP3A4 CYP2D6 CYP2B6
10 eating behavior GO:0042755 9.67 OPRM1 OPRL1 OPRK1 OPRD1
11 response to morphine GO:0043278 9.65 OPRM1 OPRK1
12 long-chain fatty acid biosynthetic process GO:0042759 9.65 CYP3A4 CYP2D6
13 estrous cycle GO:0044849 9.65 OPRM1 OPRL1 OPRK1
14 retinoic acid metabolic process GO:0042573 9.64 CYP3A7 CYP3A4
15 organic acid metabolic process GO:0006082 9.64 CYP2D6 CYP2B6
16 androgen metabolic process GO:0008209 9.63 UGT2B7 CYP3A4
17 behavior GO:0007610 9.63 OPRL1 OPRK1
18 oxidative demethylation GO:0070989 9.63 CYP3A7 CYP3A4 CYP2D6
19 neuropeptide signaling pathway GO:0007218 9.63 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
20 heterocycle metabolic process GO:0046483 9.62 CYP3A4 CYP2D6
21 estrogen metabolic process GO:0008210 9.62 CYP3A7 CYP3A4 CYP2D6 COMT
22 lipid hydroxylation GO:0002933 9.61 CYP3A7 CYP3A4
23 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.6 OPRM1 OPRL1
24 drug catabolic process GO:0042737 9.59 CYP3A4 CYP2D6
25 monoterpenoid metabolic process GO:0016098 9.58 CYP3A4 CYP2D6
26 alkaloid catabolic process GO:0009822 9.56 CYP3A4 CYP2D6
27 opioid receptor signaling pathway GO:0038003 9.56 OPRM1 OPRL1 OPRK1 OPRD1
28 conditioned place preference GO:1990708 9.55 OPRL1 OPRK1
29 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.54 OPRM1 OPRK1
30 regulation of sensory perception of pain GO:0051930 9.35 OPRM1 OPRL1 OPRK1 OPRD1 COMT
31 sensory perception GO:0007600 9.02 PNOC PDYN OPRM1 OPRL1 OPRK1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.78 CYP3A7 CYP3A4 CYP2D6 CYP2B6
2 iron ion binding GO:0005506 9.76 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3 monooxygenase activity GO:0004497 9.73 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 CYP3A7 CYP3A4 CYP2D6 CYP2B6
5 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
6 steroid hydroxylase activity GO:0008395 9.62 CYP3A7 CYP3A4 CYP2D6 CYP2B6
7 oxygen binding GO:0019825 9.58 CYP3A7 CYP3A4
8 aromatase activity GO:0070330 9.57 CYP3A7 CYP3A4
9 retinoic acid 4-hydroxylase activity GO:0008401 9.56 CYP3A7 CYP3A4
10 estrogen 16-alpha-hydroxylase activity GO:0101020 9.55 CYP3A7 CYP3A4
11 receptor serine/threonine kinase binding GO:0033612 9.54 OPRK1 OPRD1
12 testosterone 6-beta-hydroxylase activity GO:0050649 9.52 CYP3A7 CYP3A4
13 opioid receptor binding GO:0031628 9.51 PNOC PDYN
14 opioid peptide activity GO:0001515 9.49 PNOC PDYN
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.46 CYP3A7 CYP3A4 CYP2D6 CYP2B6
16 estrogen 2-hydroxylase activity GO:0101021 9.43 CYP3A7 CYP3A4 CYP2B6
17 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
18 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....